Corneal confocal microscopy demonstrates axonal loss in different courses of multiple sclerosis

Ioannis N. Petropoulos1, Kathryn C. Fitzgerald2, Jonathan Oakley3, Georgios Poniarakis1, Adnan Khan1, Hoda Gad1, Pooja George1, Dirk Deleu4, Beatriz G. Canibano4, Naveed Akhtar4, Ashfaq Shuaib4,5, Ahmed Own1, Taimur Malik2, Daniel B. Russakoff3, Joseph L. Mankowski2,6, Stuti L. Misra7, Charles N. J. McGhee7, Peter Calabresi2, Shiv Saidha1, Saadat Kamran4 & Rayaz A. Malik1*

Axonal loss is the main determinant of disease progression in multiple sclerosis (MS). This study aimed to assess the utility of corneal confocal microscopy (CCM) in detecting corneal axonal loss in different courses of MS. The results were confirmed by two independent segmentation methods. 72 subjects (144 eyes) [clinically isolated syndrome (n = 9); relapsing–remitting MS (n = 20); secondary-progressive MS (n = 22); and age-matched, healthy controls (n = 21)] underwent CCM and assessment of their disability status. Two independent algorithms (ACCMetrics; and Voxeleron deepNerve) were used to quantify corneal nerve fiber density (CNFD) (ACCMetrics only), corneal nerve fiber length (CNFL) and corneal nerve fractal dimension (CNFrD). Data are expressed as mean ± standard deviation with 95% confidence interval (CI). Compared to controls, patients with MS had significantly lower CNFD (34.76 ± 5.57 vs. 19.85 ± 6.75 fibers/mm², 95% CI − 18.24 to − 11.59, \( P < .0001 \)), CNFL [for ACCMetrics: 19.75 ± 2.39 vs. 12.40 ± 3.30 mm/mm², 95% CI − 8.94 to − 5.77, \( P < .0001 \); for deepNerve: 21.98 ± 2.76 vs. 14.40 ± 4.17 mm/mm², 95% CI − 9.55 to − 5.6, \( P < .0001 \)] and CNFrD [for ACCMetrics: 1.52 ± 0.02 vs. 1.45 ± 0.04, 95% CI − 0.09 to − 0.05, \( P < .0001 \); for deepNerve: 1.29 ± 0.03 vs. 1.19 ± 0.07, 95% CI − 0.13 to − 0.07, \( P < .0001 \)]. Corneal nerve parameters were comparably reduced in different courses of MS. There was excellent reproducibility between the algorithms. Significant corneal axonal loss is detected in different courses of MS including patients with clinically isolated syndrome.

Multiple Sclerosis (MS) is characterized by inflammation and neurodegeneration with cumulative axonal loss being the main determinant of disease progression1. However, the accurate quantification of axonal loss to help predict patient outcomes and assess therapeutic benefit in trials of neuroprotection is a major challenge. Previous studies have established that retinal optical coherence tomography2 along with non-conventional magnetic resonance imaging techniques3 such as brain volumetric analysis, diffusion tensor imaging, magnetization transfer imaging and proton magnetic resonance spectroscopy may act as potential surrogate markers of neurodegeneration in MS.

A substantial body of evidence suggests that imaging of the corneal sub-basal nerve plexus using corneal confocal microscopy (CCM) is a sensitive method to diagnose and stratify the severity of diabetic4 and other peripheral neuropathies5,6. CCM is a well-tolerated technique with high intra- and inter-operator reproducibility7. Corneal neurodegeneration is related to clinical measures of neuropathy8 and has shown comparable diagnostic performance to intraepidermal nerve fiber loss in diabetic neuropathy9. It occurs early in patients with subclinical neuropathy10 and predicts the development of clinically established diabetic neuropathy11. Altered corneal

1Research Division, Qatar Foundation, Weill Cornell Medicine-Qatar of Cornell University, PO Box 24144, Education City, Doha, Qatar. 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3Voxeleron LLC, San Francisco, CA, USA. 4Neuroscience Institute, Hamad General Hospital, Doha, Qatar. 5Department of Medicine, University of Alberta, Edmonton, AB, Canada. 6Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand. *email: ram2045@qatar-med.cornell.edu
In patients with MS compared to healthy controls, there was a significant reduction in corneal nerve fiber density (CNFD) (34.76 ± 5.57 vs. 19.85 ± 6.75, 95% CI − 18.24 to − 11.59, P < 0.0001), corneal nerve fiber length (CNFL) (12.14 ± 2.85, 95% CI 5.01 to 10.2, P < 0.0001), and CNFrD (1.47 ± 0.03, 95% CI 0.02 to 0.09, P = 0.0002). Patients with MS had a significantly higher expanded disability status scale (EDSS) score compared to CIS (2.44 ± 1.33 years, 95% CI 1.42–3.47). Patients with SPMS had a significantly higher disability status scale (EDSS) score compared to CIS (4.09 ± 2.29 vs. 0.67 ± 0.66, 95% CI − 9.05 to − 2.36, P = 0.0004) compared to CIS (2.44 ± 1.33 years, 95% CI 1.42–3.47). Patients with SPMS had a significantly higher number of relapses compared to CIS (3.70 ± 2.41 vs. 0.95 ± 0.67, 95% CI 5.49 to 1.91, P < 0.0001) and RRMS (vs. 1.70 ± 1.42, 95% CI 3.41 to 0.59, P < 0.003) with no significant difference between CIS and RRMS (95% CI 3.49 to 0.08, P = 0.06). A description of the cohort is provided in Table 1.

**ACCIMetrics.** In patients with MS compared to healthy controls, there was a significant reduction in corneal nerve fiber density (CNFD) (34.76 ± 5.57 vs. 19.85 ± 6.75, 95% CI − 18.24 to − 11.59, P < 0.0001); CNFL (19.75 ± 2.39 vs. 12.40 ± 3.30, 95% CI − 8.94 to − 5.77, P < 0.0001 and CNFrD (1.52 ± 0.07 vs. 1.45 ± 0.04, 95% CI − 0.09 to − 0.05, P < 0.0001). The difference remained significant compared to healthy controls in patients with CIS: CNFD (22.02 ± 4.35, 95% CI 5.74–19.72, P < 0.0001), CNFL (13.76 ± 2.62, 95% CI 2.69–9.3, P < 0.0001) and CNFrD (1.47 ± 0.03, 95% CI 0.02 to 0.09, P = 0.0002); RRMS: CNFD (19.48 ± 6.15, 95% CI 9.81 to 20.76, P < 0.0001), CNFL (12.14 ± 2.85, 95% CI 5.01 to 10.2, P < 0.0001) and CNFrD (1.45 ± 0.05, 95% CI 0.04–0.1, P < 0.0001).
P \lessgtr 0.0001, and SPMS: CNFD (19.29 ± 8.03, 95% CI 10.12–20.82, P < 0.0001) and CNFL (12.40 ± 3.30, 95% CI 7.56–17.24, P = 0.01). Patients with a prior history of optic neuritis (ON) compared to patients without ON (NON) showed a trend towards lower CNFD (18.98 ± 7.28, 95% CI 16.3–21.7 vs. 21.1 ± 5.85, 95% CI 18.4–23.7, P = 0.29); CNFL (11.96 ± 10.7, 95% CI 10.7–13.2 vs. 13.04 ± 11.5, 95% CI 11.5–14.6, P = 0.25); and CNFrD (1.45 ± 0.04, 95% CI 1.44–1.46 vs. 1.46 ± 0.04, 95% CI 1.44–1.48, P = 0.4) but the difference was not significant. There was no significant difference between different MS courses; consistent results were obtained after adjusting for age, sex, race and history of ON. EDSS correlated significantly with CNFD (r = − 0.32, 95% CI − 0.55 to − 0.04, P = 0.02). The detailed results are presented in Table 2 and Fig. 1D and E.

Voxeleron deepNerve. In patients with MS compared to healthy controls, there was a significant reduction in CNFL (21.98 ± 2.76 vs. 14.40 ± 4.17, 95% CI − 9.55 to − 5.6, P < 0.0001, unpaired t-test), and CNFrD (1.29 ± 0.03 vs. 1.19 ± 0.07, 95% CI − 0.13 to − 0.07, P < 0.0001). The difference remained significant compared to healthy controls in patients with CIS: CNFL (16.18 ± 3.39, 95% CI 14.84–17.52, P = 0.002) and CNFrD (1.85 ± 0.02, 95% CI 1.83–1.87, P < 0.0001); RRMS: CNFL (14.34 ± 3.76, 95% CI 11.82–16.86, P < 0.0001) and CNFrD (1.19 ± 0.06, 95% CI 1.17–1.21, P = 0.04); and SPMS: CNFL (13.74 ± 4.73, 95% CI 10.85–16.61, P < 0.0001) and CNFrD (1.18 ± 0.08, 95% CI 1.16–1.21, P = 0.04) but the difference was not significant. There was no difference between different MS courses; consistent results were obtained after adjusting for age, sex, race and history of ON. EDSS correlated significantly with CNFD (r = − 0.32, 95% CI − 0.55 to − 0.04, P = 0.02). The detailed results are presented in Table 2 and Fig. 1D and E.
CCM image analysis comparison. There was a strong linear relationship between ACCMetrics and deepNerve for CNFL ($r = 0.97$, $P < 0.0001$) and CNFrD ($r = 0.94$, $P < 0.0001$). Spearman correlations were also consistent after adjusting for age, sex, race and history of ON and similar correlations were observed using Pearson correlations. The intra-class correlation co-efficient (ICC) was high for CNFL (ICC 0.82, 95% CI 0.74–0.87) and CNFrD (ICC 0.83, 95% CI 0.76–0.88) indicating excellent reproducibility. Bland–Altman analysis (Table 3 and Fig. 2A,B) showed that fully automated CCM image analysis performed by two independent segmentation methods on the same set of images has generally high agreement for measures of length and fractal analysis once we accounted for differences in the variability across levels of measurement (following approaches described by Bland and Altman30 for more complex associations between measures).

Discussion

Over the last two decades, CCM has emerged as a powerful surrogate marker of peripheral neuropathy4–6. We have shown that corneal nerve loss is related to the genotype, and neurological disability assessed using the Scale for the Assessment and Rating of Ataxia, Friedreich’s Ataxia Rating Scale and quantitative gait assessment in patients with Friedreich’s ataxia6. More recent studies have shown that corneal axonal loss also occurs in central neurodegenerative conditions and is associated with the severity of neurological deficits16,19–21 and cognitive impairment18. Accurate quantification of corneal nerve alterations in CCM images is challenging due to the small image size, variable contrast and lack of universally accepted criteria to identify corneal nerve loss. Nevertheless, earlier studies4,31 have shown that both manual and automated measures of corneal nerve morphology (CNFD, CNFL, CNFrD) are a robust means to assess the severity of peripheral neuropathy. In this study, we have applied two independently validated automated segmentation algorithms27,29 on the same set of CCM images from patients with MS and healthy individuals.

The first finding in our study was a significant reduction in CNFD, CNFL and CNFrD in patients with CIS, RRMS and SPMS compared to healthy controls. Whilst these findings confirm the results of previous smaller studies showing corneal nerve loss in patients with predominantly RRMS19–22, we now additionally demonstrate significant corneal nerve loss in patients with CIS and SPMS. Indeed, previous studies have shown a comparable degree of retinal nerve fiber layer thinning in CIS32 and other courses of MS33. Moreover, corneal nerve loss was comparable between patients with RRMS and SPMS. Previous studies19–22 have reported an association between corneal axonal loss to central neurodegeneration in MS may be questionable. However, all studies to date have consistently demonstrated corneal nerve loss and related it to neurological disability in different cohorts of patients with MS19–23. Indeed, there is evidence of substantial neurodegeneration in the spinal cord of patients with MS which contributes to significant disability34. Diffuse synaptic pathology in the

| Parameter (n = 72) | Mean difference (95% CI) | Lower LOA | Upper LOA | Range |
|-------------------|--------------------------|------------|-----------|-------|
| CNFL              | $-2.07 (± 0.69)$          | $-5.40$    | $1.27$    | $6.66$ |
| CNFrD             | $-0.25 (± 0.01)$          | $-0.32$    | $-0.18$   | $0.14$ |

Table 3. Bland–Altman analysis: Voxeleron deepNerve versus ACCMetrics. CI confidence interval, CNFL corneal nerve fiber length, CNFrD corneal nerve fractal dimension, LOA limits of agreement.
Grey matter has also been shown to selectively affect distal axonal density due to reduced axonal transport\textsuperscript{35}. The lack of difference between different MS courses in the present study may reflect underlying differences in disease duration with relatively mild neurological disability, especially in patients with SPMS, and a small cohort size.

The second main finding in our study was that ACCMetrics and Voxeleron deepNerve measurements of corneal nerve loss were strongly associated, despite the two algorithms employing different underlying segmentation methods to quantify CCM images. ACCMetrics uses a trained feature detection model based on a set of predefined criteria for nerve fiber segmentation provided by a ground truth dataset. Voxeleron deepNerve\textsuperscript{29} applies a dense series of overlapping filters, pre-learned using a deep neural network architecture, to the original image, thereby generating a nerve probability image and the final delineation. Both algorithms have strengths; ACCMetrics has been validated in multiple studies\textsuperscript{4,9,12} and can measure additional metrics such as CNFD and corneal nerve branch density, which may provide an insight into nerve regeneration in clinical trials of disease modifying therapies\textsuperscript{13,15,36}. On the other hand, Voxeleron deepNerve is capable of segmenting various types of corneal nerve images such as immunohistochemically stained whole corneal mounts\textsuperscript{28} and in-vivo CCM images and has an advantage when quantifying larger corneal nerve maps. Segmentation accuracy by deepNerve may also be less liable to image noise as a result of poor patient cooperation or less experienced examiners, resulting in sub-optimal image quality. This is because deep learning networks can detect image features while retaining their spatial relationship. They furthermore facilitate iterative learning by backpropagating this information into the network. This is relevant to corneal nerve fibers, which appear as sequences of neighboring nerve pixels against a dark background. Another advantage is that deep learning performance is directed by a loss function, which determines how accurate the final output is in relation to the input data, allowing a tradeoff between false positives and false negatives. Clearly, automation is a major strength of both methods as it minimizes bias, accelerates image quantification, and makes CCM more suitable for prospective and multi-center trials. Both techniques are subject to selection bias if the predefined criteria or training dataset respectively are not sufficiently inclusive. However, deep learning models may be superior to traditional machine learning methods due to their versatility.

The present study has some limitations. First, our image sampling approach may have introduced selection bias favoring lower mean values compared to the true mean of the central subbasal nerve plexus\textsuperscript{37} especially for patients with more advanced disability. Second, the results from this study cannot be generalized to all deep learning algorithms. As the field of artificial intelligence is constantly evolving, a system with a different network architecture may produce different results. Third, although no participant was clinically diagnosed with trigeminal neuralgia, trigeminal-related pathology may have contributed to the observed differences. Reassuringly, an earlier study\textsuperscript{38} found no difference in corneal nerve density in patients with and without trigeminal neuralgia-related symptoms. In summary, we have shown significant corneal axonal loss in different courses of MS and for the first time in patients with CIS using two independent image segmentation algorithms. These data urge the need for further prospective CCM studies in larger cohorts of patients with different courses of MS evaluating additional morphological features, such as the inferior whorl\textsuperscript{19}, and Langerhans cells\textsuperscript{19,24} longitudinally and in relation to trigeminal neuralgia and therapeutic intervention.

Methods

Study subjects. This is a single-center, cross-sectional, observational study conducted between February 2017 and March 2018. Patients with CIS (n = 9), RRMS (n = 20) and SPMS (n = 22) attending the neurology outpatient department of Hamad General Hospital in Doha, Qatar, and age-matched, healthy controls (n = 21) were recruited (Fig. 3). Main outcome measures were CNFD, CNFL and CNFrD quantified by ACCMetrics and

Figure 3. Flowchart of the study cohort.
Voxeleron deepNerve respectively. This study adhered to the tenets of the declaration of Helsinki and obtained prospective approval from the institutional review board of Weill Cornell Medicine-Qatar (no. 15-00064). Informed, written consent for research was obtained from all subjects prior to participation. Reporting of results in this study followed the STROBE guidelines. Inclusion criteria were diagnosis of CIS or MS based on the revised McDonald’s criteria (2010) and age 18–75 years. Patients with MS and healthy controls who were contact lens users, diagnosed with ophthalmologic disease (e.g., glaucoma, vitreoretinal or corneal disorders), had active ON or had undergone refractive surgery were excluded. Patients with other metabolic, ophthalmologic, rheumatologic, or neurologic disorders that may cause neuropathy were excluded from participation in the study based on HbA1c, anti-nuclear antibody, serum B12/folate and immunoglobulins and a detailed medical history. All underlying anonymized data from the analysis presented in this manuscript are available for use on request to the corresponding author.

Clinical and demographic information. Past medical history including ON history, disease duration and MS-associated relapses were obtained by a physician neurologist. The EDSS by Kurtzke was performed prior to CCM scans to rate neurological impairment in patients with MS. Briefly, the EDSS is a physician-administered composite for functional assessment of the central nervous system. It consists of an ordinal scale ranging from 0 (normal neurological function) to 10 (death due to MS) in 0.5 increments (from EDSS > 1 onwards). Scores from 0 to 4 evaluate general neurological function, 4–6 focuses on walking ability and scores greater than 6 indicate loss of neurological independence.

Corneal confocal microscopy. All study participants underwent CCM (Heidelberg Retinal Tomograph III Rostock Cornea Module, Heidelberg Engineering GmbH, Heidelberg, Germany). This device uses a 670 nm wavelength helium neon diode laser, which is a class I laser and therefore does not pose any ocular safety hazard. A 63 × objective lens with a numerical aperture of 0.9 and a working distance, relative to the applanating cap (TomoCap®, Heidelberg Engineering GmbH, Heidelberg, Germany) of 0.0 to 3.0 mm is used. The size of each two-dimensional image produced is 384 μm × 384 μm with a 15° × 15° field of view and 10 μm/pixel transverse optical resolution. To perform the CCM examination, local anesthetic (0.4% benoxinate hydrochloride, Chau-vin Pharmaceuticals, Chefaro, UK) was used to anaesthetize each eye and Viscoat® (Carbomer 980, 0.2%, Novartis, UK) was used as the coupling agent between the cornea and the applanating cap. All subjects were asked to fixate on an outer fixation light throughout the CCM scan and an externally coupled camera was used to correctly position the applanating cap onto the central cornea. Images were acquired using the “section” mode on the Heidelberg eye explorer and the scanning duration for both eyes was 5–7 min. Based on depth, contrast and focus position 6 non-overlapping images/subject (3 out of 15 images per eye) from the central sub-basal nerve plexus were selected for analysis as per previously validated protocol. In the present study, CCM results are presented as an average of all 6 images per patient. Investigators were masked to the MS course, disability severity and medication history during CCM examination and image selection was performed by a different investigator without knowledge of the participant. CCM image examples from a HC and patients with CIS, RRMS and SPMS are presented in Fig. 4.

Image analysis. CCM images from both eyes (n = 448) were analyzed using two independent, purpose-designed CCM image segmentation algorithms: ACCMetrics (MA Dabbah, X Chen, J Graham & RA Malik, University of Manchester, Manchester, UK) and Voxeleron deepNerve (Dr. JL Mankowski, Johns Hopkins University School of Medicine, Baltimore, MD, USA; and Drs. JD Oakley and DB Russakoff, Voxeleron LLC, San Francisco, CA, USA hold a patent relating to aspects of the algorithm’s implementation) at the same time in different geographical locations. CCM image examples analyzed by ACCMetrics and Voxeleron deepNerve are presented in Fig. 4A,D,G,J.

ACCMetrics. ACCMetrics is a validated CCM image segmentation algorithm which measures CNFD (fibers/mm²)—the number of main nerve fibers per image divided by the area of the image, CNFL (mm/mm²)—the sum of the length of all nerves per image (main nerves + branches) and CNFrD—nerve fiber complexity per image. Briefly, automated corneal nerve fiber detection consists of two steps: (1) CCM image enhancement and nerve fiber detection and (2) quantification of the morphometric parameters. A dual-model feature descriptor combined with a neural network classifier was used to train the computer to distinguish nerve fibers from the background. In the quantification process, end points and branch points of the detected nerve fibers were used to estimate the length of all nerves per image (main nerves + branches) and CNFrD—nerve fiber complexity. ACCMetrics was shown to be highly reproducible using a box counting method. Analyzed image examples by ACCMetrics are shown in Fig. 4B,E,H,K.

Voxeleron deepNerve. This image segmentation algorithm termed deepNerve extends the earlier work of Dorsey et al. using a deep learning-based approach for the detection and analysis of corneal subbasal nerves. This is a supervised learning approach where pixel wise segmentation was compared with manually traced data using NeuronJ in 60 images acquired from the University of Auckland. In this study, it served as a training set, with the evaluation (test set), being done based on the image data described in the methods section (study subjects). The neural network architecture chosen was a U-Net, with three encoding and decoding layers. Categorical cross-entropy was used as the loss function and models and model parameters were evaluated based on a leave one subject out cross validation approach using the Auckland data set. The pre-processing involved denoising and flat fielding of the image data to account for noise and intensity inhomogeneity, respectively, and
the post-processing thresholds skeletonize the output nerve probability map from the neural network to generate the final nerve fiber segmentation. This enables reporting of CNFL (mm/mm²) and CNFrD. Analyzed image examples by Voxeleron deepNerve are shown in Fig. 4C,F,I,L.

**Statistical analysis.** Prism (version 8.4.3 for Mac, GraphPad software Inc., CA, USA) and MatLab (version v2019b for Windows, Mathworks Inc., USA) were used for the statistical analyses and graphic illustrations. A Shapiro–Wilk test was used to assess data for normality ($P < 0.05$). Significant deviations from normality were not observed. We used an unpaired $t$-test or one-way analysis of variance (Post-hoc Sidak’s test) to compare the results between the MS and healthy controls groups and between the CIS, RRMS, SPMS groups and healthy controls respectively. A two-sided $P$ value was favored on the assumption of unequal population means and a $P < 0.05$ was considered significant. Spearman correlations and the ICC were calculated to assess the relationship between ACCMetrics and Voxeleron deepNerve; secondary analyses adjusted Spearman correlation for age, sex, and race. Spearman correlations were adjusted using methods described by Liu et al. Agreement between the two analysis methods was assessed by means of Bland–Altman plots (average vs. the difference between values) and calculating the upper and lower limits of agreement. We also considered Bland Altman plots that additionally modeled the variability in the difference as a function of the level of measurement that can account for differences in the SD across the two measures. The ICC was estimated using a linear mixed effects model with a random effect to estimate within and between person error (for two measures per person), following methods originally described by Shrout et al. Generally, a higher ICC with a lower limit of the 95% CI $\geq 0.75$ indicates excellent reproducibility.

Received: 16 June 2021; Accepted: 19 October 2021
Published online: 04 November 2021

**References**

1. Ferguson, B., Matyszak, M. K., Esiri, M. M. & Perry, V. H. Axonal damage in acute multiple sclerosis lesions. *Brain* **120**, 393–399 (1997).
2. Rothman, A. et al. Retinal measurements predict 10-year disability in multiple sclerosis. *Ann. Clin. Transl. Neurol.* **6**, 222–232 (2019).
3. Bakshi, R. et al. MRI in multiple sclerosis: current status and future prospects. *Lancet Neurol.* **7**, 615–625 (2008).
4. Petropoulos, I. N. et al. Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy automated detection of diabetic neuropathy. *Invest. Ophthalmol. Vis. Sci.* **55**, 2071–2078 (2014).
5. Stettner, M. et al. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. *Ann. Clin. Transl. Neurol.* **3**, 88–100 (2015).
6. Pagovitch, O. E. et al. Corneal confocal microscopy: Neurologic disease biomarker in Friedreich ataxia. *Ann. Neurol.* **84**, 893–904 (2018).
7. Petropoulos, I. N. et al. Repeatability of in vivo corneal confocal microscopy to quantify corneal nerve morphology. *Cornea* **32**, e83–e89 (2013).
8. Sivaskandarajah, G. A. et al. Structure-function relationship between corneal nerves and conventional small-fiber tests in type 1 diabetes. *Diabetes Care* **36**, 2748–2753 (2013).
9. Chen, X. et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: Comparing corneal confocal microscopy with intraepidermal nerve fiber density. *Diabetes Care* **38**, 1138–1144 (2015).
10. Asghar, O. et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. *Diabetes Care* **37**, 2643–2646 (2014).
11. Pritchard, N. et al. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. *Diabetes Care* **38**, 671–675 (2015).
12. Chen, X. et al. Corneal nerve fractal dimension: a novel corneal nerve metric for the diagnosis of diabetic sensorimotor polyneuropathy. *Invest. Ophthalmol. Vis. Sci.* **59**, 1113–1118 (2018).
13. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. *Investig. Ophthalmol. Vis. Sci.* **58**, BI052–BI060 (2017).
14. Tavakoli, M. et al. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. *Diabetes** **62**, 254–260 (2013).
15. Aizmendi, A. et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. *Diabetologia* **62**, 1478–1487 (2019).
16. Kass-Iliyia, L. et al. Small nerve fiber neuropathy in Parkinson’s disease: A clinical, pathological and corneal confocal microscopy study. *Parkinsonism Relat. Disord.* **21**, 1454–1460 (2015).
17. Misra, S. L., Kersten, H. M., Rooborgh, R. H., Danesh-Meyer, H. V. & McGhee, C. N. Corneal nerve microstructure in Parkinson’s disease. *J. Clin. Neurosci.* **39**, 53–58 (2017).
18. Ponirakis, G. et al. Association of corneal nerve fibre measures with cognitive function in dementia. *Ann. Clin. Transl. Neurol.* **6**, 689–697 (2019).
19. Bitirgen, G., Akpinar, Z., Malik, R. A. & Ozkagnici, A. Use of corneal confocal microscopy to detect corneal nerve loss and increased dendritic cells in patients with multiple sclerosis. *JAMA Ophthalmol.* **135**, 777–782 (2017).
20. Mikolajczak, J. et al. Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. *Mult. Scler.* **23**, 1847–1853 (2017).
21. Petropoulos, I. N. et al. Corneal confocal microscopy: An imaging endpoint for axonal degeneration in multiple sclerosis. *Invest. Ophthalmol. Vis. Sci.* **58**, 3677–3681 (2017).
22. Testa, V. et al. Neuroaxonal degeneration in patients with multiple sclerosis: An optical coherence tomography and in vivo corneal confocal microscopy study. *Cornea* **39**, 1221–1226 (2020).
23. Fernandes, D. et al. Corneal subbasal nerve plexus evaluation by in vivo corneal confocal microscopy in multiple sclerosis: A potential new biomarker. *Curr. Eye Res.* **46**, 1452–1459 (2021).
24. Khan, A. et al. Corneal immune cells are increased in patients with multiple sclerosis. *Transl. Vis. Sci. Technol.* **10**, 19 (2021).
25. da Silva, C. J. et al. Trigeminal involvement in multiple sclerosis: Magnetic resonance imaging findings with clinical correlation in a series of patients. *Mult. Scler.* **11**, 282–285 (2005).
26. Love, S., Graddide, T. & Coolham, H. B. Trigeminal neuralgia due to multiple sclerosis: Ultrastructural findings in trigeminal rhizotomy specimens. *Neuropathol. Appl. Neurobiol.* **27**, 234–244 (2001).
27. Dabbah, M. A., Graham, J., Petropoulos, I. N., Tavakoli, M. & Malik, R. A. Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. *Med. Image Anal.* **15**, 738–747 (2011).
28. Dorney, J. L. et al. Loss of corneal sensory nerve fibers in SIV-infected macaques: An alternate approach to investigate HIV-induced PNS damage. *Am. J. Pathol.* **184**, 1652–1659 (2014).
29. Oakley, J. D. et al. Deep learning-based analysis of macaque corneal sub-basal nerve fibers in confocal microscopy images. *Eye Vis.* **7**, 27 (2020).
30. Bland, J. M. & Altman, D. G. Measuring agreement in method comparison studies. *Stat. Methods Med. Res.* **8**, 135–160 (1999).
31. Perkins, B. A. et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: A pooled multinational consortium study. *Diabetologia* **61**, 1856–1861 (2018).
32. Oberwahrenbrock, T. et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. *Mult. Scler.* **19**, 1887–1895 (2013).
33. Costello, F., Hodge, W., Pan, Y. J., Freedman, M. & DeMeulemeester, C. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. *J. Neurol. Sci.* **281**, 74–79 (2009).
34. Vogt, J. et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. *Ann. Neurol.* **66**, 310–322 (2009).
35. Jürgens, T. et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. *Brain** **139**, 39–46 (2016).
36. Lewis, E. J. et al. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. *Neurology* **88**, 2294–2301 (2017).
37. Kim, G. et al. Assessing the reproducibility of quantitative in vivo confocal microscopy of corneal nerves in different corneal locations. *Cornea* **32**, 1331–1338 (2013).
38. Petropoulos, I. N. et al. The inferior whorl for detecting diabetic peripheral neuropathy using corneal confocal microscopy for detecting DPN. *Invest. Ophthalmol. Vis. Sci.* **56**, 2498–2504 (2015).
39. Von Elm, E. et al. The strengthen the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Ann. Intern. Med.* **147**, 573–577 (2007).
40. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann. Neurol.* **69**, 292–302 (2011).
41. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* **33**, 1444–1452 (1983).
42. Vagenas, D. et al. Optimal image sample size for corneal nerve morphometry. *Optom. Vis. Sci.* **89**, 812–817 (2012).
43. Mankowski, J. L., Oakley, J. D. & Russakoff, D. B. Automated methods to count corneal subbasal nerves (2017).

44. Meijering, E. et al. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. *Cytometry* **58**, 167–176 (2004).
45. Misra, S. L. et al. In vivo confocal microscopy of corneal nerves: an ocular biomarker for peripheral and cardiac autonomic neuropathy in type 1 diabetes mellitus: ocular biomarker for diabetic neuropathy. *Invest. Ophthalmol. Vis. Sci.* **56**, 5060–5065 (2015).
46. Liu, Q., Li, C., Wanga, V. & Shepherd, B. E. Covariate-adjusted Spearman’s rank correlation with probability-scale residuals. *Biometrics* **74**, 595–605 (2018).
47. Shront, P. E. & Fleiss, J. L. Intraclass correlations: Uses in assessing rater reliability. *Psychol. Bull.* **86**, 420 (1979).
48. Lee, J., Koh, D. & Ong, C. Statistical evaluation of agreement between two methods for measuring a quantitative variable. *Comput. Biol. Med.* **19**, 61–70 (1989).

**Acknowledgements**
This work was kindly supported by Qatar National Research Fund (Grant Number BMRP 20038654), a Merck Grant for Multiple Sclerosis Innovation (Grant Number 201701.10249.POT) and the Blaustein Pain Research Fund, Johns Hopkins University School of Medicine (Joseph L. Mankowski). Dr. Stuti L. Misra was supported by a Fulbright New Zealand Travel Award.

**Author contributions**
I.N.P. acquired and analyzed data and wrote the first draft. K.C.F., J.O., G.P., A.K., H.G., P.G., D.D., B.G., N.A., A.S., A.O., T.M., D.B.R., J.L.M., S.L.M., C.N.J.M., P.C., S.S., S.K. contributed to data acquisition and analysis and reviewed the final draft. R.A.M. conceptualized and designed the study and reviewed the final draft.

**Competing interests**
Drs. Ioannis N. Petropoulos, Kathryn C. Fitzgerald, Georgios Poniarakis, Adnan Khan, Hoda Gad, Pooja George, Dirk Delue, Beatriz Canibano, Naveed Akhtar, Ashfaq Shuaib, Ahmed Own, Stuti L. Misra, Charles N.J. McGhee and Saadat Kammam report no financial disclosures. Dr. Jonathan Oakley is an employee of Voxeleron LLC and holds a patent application relating to aspects of the algorithm’s implementation (Voxeleron deepNerve). Dr. Taimur M. Malik owns stock in Pfizer, Cymba Therapeutics, Moderna, Boston Scientific and Walgreens. Dr. Daniel B Russakoff is an employee of Voxeleron LLC and holds a patent application relating to aspects of the algorithm’s implementation (Voxeleron deepNerve). Dr. Joseph L Mankowski holds a patent application relating to aspects of the algorithm’s implementation (Voxeleron deepNerve). Dr. Peter Calabresi is PI on grants to Johns Hopkins from Annexon and Biogen and has received consulting honoraria from Biogen and Disarm Therapeutics for serving on scientific advisory boards. Dr. Shiv Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology, and has served on scientific advisory boards for Biogen, Genzyme, Genentech Corporation, EMD Serono, and Celgene. He is the PI of investigator-initiated studies funded by Genentech and Biogen, was the site investigator of a trial sponsored by MedDay Pharmaceuticals and received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. Dr. Rayaz A. Malik is a PI on grants from Proctor and Gamble and Pfizer and has received consulting honoraria for serving on advisory boards for Novo Nordisk, Aventis Pharma and Proctor and Gamble.

**Additional information**
Correspondence and requests for materials should be addressed to R.A.M. Reprints and permissions information is available at www.nature.com/reprints. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2021